Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

FDA approves SynCardia Total Artificial Heart for destination therapy study

Jan. 12, 2015

China investigators divulge NEP inhibitor prodrugs

Jan. 9, 2015

FDA responds to Cesca's IDE application for pivotal critical limb ischemia trial

Jan. 8, 2015

United Therapeutics signs agreement with DEKA for development of Remodulin pump system

Jan. 5, 2015

Medtronic submits premarket approval application for SynchroMed II

Dec. 31, 2014

FDA issues complete response letter for Actavis' nebivolol/valsartan NDA

Dec. 29, 2014

Actelion files NDA for selexipag in pulmonary arterial hypertension

Dec. 24, 2014

Further phase III data reveal efficacy of LCZ-696 in hypertension and heart failure

Dec. 22, 2014

Pozen receives second complete response letter from FDA regarding Yosprala

Dec. 18, 2014

Preclinical results presented for BB-R12, a novel gene therapy for heart failure

Dec. 18, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 24, 2026.
To viral or not to viral: In vivo CAR T debates delivery tech
BioWorld
The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 21, 2026
KBN-2201 reverses key features of Alzheimer’s in mice
BioWorld Science
Researchers from Ajou University School of Medicine reported the preclinical efficacy of KBN-2201 in a mouse model of late-stage Alzheimer’s disease.
In vivo click ADCs could address tumor heterogeneity
BioWorld
Researchers at Washington University in St. Louis have used click chemistry to link a second antibody to a pre-existing antibody-drug conjugate (ADC) in vivo. In...